Observational studyCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020
Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.
Observational study in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The Role of Circulating Protein and Metabolite Biomarkers in the Development of Pancreatic Ductal Adenocarcinoma (PDAC): A Systematic Review and Meta-analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Pooled it
- Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.Gastroenterology · 2021Trial
- Polygenic scores for risk of pancreatic ductal adenocarcinoma: evaluation of novel and published models.NPJ precision oncology · 2026Article
- Leveraging the Electronic Health Record for Early Detection of Pancreatic Cancer Among 9.4 Million US Veterans.Clinical and translational gastroenterology · 2026Article
- Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records.Cell reports. Medicine · 2025Article
- Harnessing artificial intelligence for detection of pancreatic cancer: a machine learning approach.Clinical and experimental medicine · 2025Article
- A pancreatic cancer risk prediction model (Prism) developed and validated on large-scale US clinical data.EBioMedicine · 2023Article
- An Integrative Pancreatic Cancer Risk Prediction Model in the UK Biobank.Biomedicines · 2023Article
- Diagnostic ability of deep learning in detection of pancreatic tumour.Scientific reports · 2023Article
- A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories.Nature medicine · 2023Article
- The age-dependent association of risk factors with pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Article
- Review
- Current status of inherited pancreatic cancer.Hereditary cancer in clinical practice · 2022Review
- Hepatocellular Carcinoma Risk Prediction in the NIH-AARP Diet and Health Study Cohort: A Machine Learning Approach.Journal of hepatocellular carcinoma · 2022Article
- Inherited Pancreatic Cancer Syndromes and High-Risk Screening.Surgical oncology clinics of North America · 2021Review
- Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer.JCO clinical cancer informatics · 2021Article
- Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk.Frontiers in oncology · 2021Article
- Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundPancreatic cancer is the third leading cause of cancer death in the United States, and 80% of patients present with advanced, incurable disease. Risk markers for pancreatic cancer have been characterized, but combined models are not used clinically to identify individuals at high risk for the disease.
methodsWithin a nested case-control study of 500 pancreatic cancer cases diagnosed after blood collection and 1,091 matched controls enrolled in four U.S. prospective cohorts, we characterized absolute risk models that included clinical factors (e.g., body mass index, history of diabetes), germline genetic polymorphisms, and circulating biomarkers.
resultsModel discrimination showed an area under ROC curve of 0.62 via cross-validation. Our final integrated model identified 3.7% of men and 2.6% of women who had at least 3 times greater than average risk in the ensuing 10 years. Individuals within the top risk percentile had a 4% risk of developing pancreatic cancer by age 80 years and 2% 10-year risk at age 70 years.
conclusionsRisk models that include established clinical, genetic, and circulating factors improved disease discrimination over models using clinical factors alone. IMPACT: Absolute risk models for pancreatic cancer may help identify individuals in the general population appropriate for disease interception.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.